Payment Models and Practice Changes: Meeting Requirements of OCM & MACRA

Access Activity

Overview / Abstract:

Recent legislation and policy has fast-tracked the shift of healthcare payment from volume- to value-based reimbursement under the Medicare Access and CHIP Reauthorization Act (MACRA) for oncology care. Today, oncologists have the option to be reimbursed for Medicare patients under the CMS Oncology Care Model (OCM), an alternative payment model spanning a 6-month chemotherapy episode-of-care. This activity will provide insight into the program’s structure and challenges. It will also review new provider models and use of data systems to improve cancer care delivery.

Educational Objectives
At the conclusion of this session, participants should be able to demonstrate the ability to:

-Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care

-Understand the development of quality measures as a component of new payment models


Jan 24, 2019


Dietetics / Dietitian CE, Informatics / Coding / Billing CE, Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

AACME - 1.50 AMA PRA Category 1 Credit; ACPE - 1.50 hours (0.15 CEUs); ANCC - 1.6 contact hours


Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology

Presenters / Authors / Faculty

Therese Marie Mulvey, MD
Director of Quality Safety and Value
Massachusetts General Hospital Cancer Center
Director Breast Oncology
MGH/North Shore Cancer Center
Boston, MA

Charles Saunders, MD
Chief Executive Officer
Integra Connect
West Palm Beach, FL

Activity Specialities / Related Topics

Regulatory / Compliance / Risk Mgt, Pharmacology, Oncology / Cancer / Radiation Therapy, Nutrition / Dietary, Managed Care, Hematology, Genetics, Case Management, Administration / Management, Reimbursement / Coding / Billing

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit

Keywords / Search Terms

Rockpointe OCM, MACRA, Medicare Access and CHIP Reauthorization Act, CMS Oncology Care Model, oncology, hematology,value-based reimbursement, formulary, financial advocates, nutrition plans, psychological assessment, genetic counseling, navigation, payment model Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.